



ISSN (E): 2277- 7695
 ISSN (P): 2349-8242
 NAAS Rating: 5.03
 TPI 2018; 7(12): 418-422
 © 2018 TPI
 www.thepharmajournal.com
 Received: 15-10-2018
 Accepted: 17-11-2018

Arun Kumar Kuna
 GITAM Institute of Pharmacy,
 GITAM University, Gandhi
 Nagar, Rushikonda,
 Visakhapatnam, Andhra
 Pradesh, India

Ganapaty Seru
 GITAM Institute of Pharmacy,
 GITAM University, Gandhi
 Nagar, Rushikonda,
 Visakhapatnam, Andhra
 Pradesh, India

GV Radha
 GITAM Institute of Pharmacy,
 GITAM University, Gandhi
 Nagar, Rushikonda,
 Visakhapatnam, Andhra
 Pradesh, India

Analytical method development and validation for the estimation of Imatinib mesylate and its acid impurity in pharmaceutical formulation by RP-HPLC

Arun Kumar Kuna, Ganapaty Seru and GV Radha

Abstract

A simple, specific and accurate reverse phase high performance liquid chromatographic method was developed for the determination of Imatinib mesylate and its Acid Impurity in pharmaceutical dosage form. The column used was HiQ Sil C18 (250 x 4.6 mm, 5 μ m), with mobile phase containing methanol and Acetate Buffer pH 3.5 in the ratio of 80: 20 v/v, the flow rate was 1.0 mL/ min and eluent was monitored at 273nm. The retention time for Imatinib mesylate was 8.083 and for Acid Impurity it is 6.208. The proposed method was validated and successfully applied to the estimation of Imatinib mesylate and Acid Impurity in formulations.

Keywords: RP-HPLC, validation, Imatinib, acid, impurity

Introduction

Imatinib mesylate is a molecule that inhibits the c-Abl protein-tyrosine kinase, a kinase specifically important for proliferation of chronic myelogenous leukemia (CML). A translocation event between chromosomes 9 and 22 generates the Philadelphia chromosome, which then produce the Bcr-Abl fusion protein with aberrant kinase activity that promotes rapid cell proliferation. Imatinib binds up this crucial kinase, halting CML related growth. Imatinib mesylate has further been displayed to inhibit PDGFR and tyrosine kinases associated with c-Kit. The structure of Imatinib mesylate is shown in Figure 1.




Fig 1: Structure of Imatinib mesylate

Imatinib Mesylate is chemically known as 4-[[4-(4-Methyl-1-piperazinyl) methyl]-N-[4-methyl-3-[[4-(3-pyridinyl) - 2 -pyrimidinyl] amino] phenyl] benzamid methane sulfonate and has a chemical formula C₂₉H₃₁N₇O•CH₃SO₃H. A molecular weight of Imatinib mesylate is 589.7 g/mol. Imatinib mesylate is a white to creamish yellow crystalline powder. It is freely soluble in water, 0.1 N HCl and methanol. Acid impurity is chemically known as 4-[[4-(4-methyl-1-piperazinyl) methyl] benzoic acid dihydrochloride. Regulatory requirements for the identification, qualification, and control of Impurities in drug substances and their formulated products are now being explicitly defined, particularly through the International Conference on Harmonization (ICH)(1-2). Analytical methods have been reported in the literature for estimation of Imatinib mesylate and its Impurities in bulk drugs and formulations (3-6). The aim of current study was to develop and validate HPLC method for the simultaneous determination of Imatinib mesylate and acid Impurity.

Correspondence

Arun Kumar Kuna
 GITAM Institute of Pharmacy,
 GITAM University, Gandhi
 Nagar, Rushikonda,
 Visakhapatnam, Andhra
 Pradesh, India

Materials and Methods

Chemicals and Reagents

Imatinib mesylate - analytical sample was obtained as a gift sample from Nishka Labs, Hyderabad and its Acid Impurity was procured from Nishka Labs, Hyderabad.

All chemicals and reagents used were of AR grade and all the solvents used were of HPLC grade. Methanol HPLC Grade, Acetonitrile HPLC Grade was of Merck Chemicals, Mumbai while Hydrochloric acid and Ammonium Acetate AR Grade was of S.D. Fine Chemical Industries, Mumbai. Double distilled water prepared at laboratory scale using ELGA water purification system, was used throughout the study. GLEEVAC film coated tablets (Novartis) were procured from the local pharmacy labelled to contain Imatinib mesylate equivalent to 100 mg of Imatinib free base.

Instrumentation

HPLC system used was JASCO system equipped with Model PU 2080 Plus pump, Rheodyne Sample injection port (20 μ L), MD 2010 PDA detector and Borwin-PDA software (version 1.5). A chromatographic column HiQ Sil C18 (250 x 4.6 mm, 5 μ m) was used for separation. All weighing were done on Shimadzu balance Model AY-120.

Chromatographic Conditions: Isocratic Procedure

Chromatographic separation carried using methanol and acetate buffer pH 3.5 in the ratio of 80:20 v/v as the mobile phase which gave good resolution and acceptable peak parameters. Separation was carried out at flow rate of 1 ml/min and detection at 273 nm. The peak purity was checked with the PDA detector. The mobile phase was filtered through a 0.45 μ nylon membrane filter prior to use. The sample injection volume was 20 μ l.

Preparation of Mobile Phase

Acetate Buffer pH 3.5 was prepared by dissolving 25 gm of ammonium acetate in 25 ml water. Added 38 ml of 7 M HCl adjusted the pH to 3.5 with 2 M HCl or 6 M ammonia and diluted with water to 100 ml. Mobile phase was prepared by mixing methanol and Acetate Buffer pH 3.5 in the ratio of 80:20 v/v. It was then filtered through 0.45 μ m membrane filter paper using filtration assembly and then sonicated on ultrasonic water bath for 15 min.

Preparation of Solution

Standard Solution

A standard stock solution 'A' containing 100 μ g/ml of Acid Impurity was prepared by dissolving 10 mg of Acid Impurity in methanol in a 100 ml volumetric flask. The stock solution 'B' was further prepared by diluting appropriate amount with methanol to get 10 μ g/ml solution of Acid Impurity. The Imatinib mesylate standard stock solution 'C' containing 1000 μ g/ml was prepared using appropriate amount of Imatinib mesylate reference standard dissolved in methanol.

Resolution Solution

Resolution solution 'D' was prepared by mixing 1 ml of Imatinib mesylate standard stock solution C and 5 ml of Impurity stock solution B, diluted up to 100 ml with methanol. This resolution solution was containing 10 μ g/ml of Imatinib mesylate and 0.5 μ g/ml of Impurity.

Sample Solution (for Formulation Analysis)

To determine the content of Imatinib mesylate in conventional

tablet, twenty tablets were weighed (each tablet containing Imatinib mesylate equivalent to 100 mg of Imatinib free base); their mean weight was determined and was finely powdered. The weight of the tablet powder equivalent to 100 mg of Imatinib mesylate was transferred into a 100 ml volumetric flask containing 80 ml methanol and sonicated for 5 min. to ensure complete dissolution of drug. The extract was filtered, residue was washed with methanol and volume was made up to the mark by adding washings to the flask. Appropriate volume of above solution was further diluted suitably with methanol to give 20 μ g/ml of Imatinib mesylate and 20 μ l was injected into HPLC system, under the conditions described above.

System Suitability

System suitability parameters were evaluated to verify that the analytical system is working properly and can give accurate and precise results using 20 μ l resolution solution 'D' (10 μ g/ml of Imatinib mesylate and 0.5 μ g/ml of Impurity). Parameters such as tailing factor, resolution, peak area were evaluated. The % RSD less than 2.0 for six replicate injections and theoretical plates not less than 2000 was set as acceptance criteria for system suitability of the proposed assay method.

Analytical Method Validation

The method was validated for linearity, range, accuracy, precision, sensitivity, specificity and robustness in accordance with ICH guidelines^[1-2].

Linearity and Range

Linearity of Imatinib mesylate was determined over a range of 10-60 μ g/ml, while for the Acid Impurity a range of 0.5 μ g/ml to 3 μ g/ml was selected for linearity study. Calibration curve was drawn by plotting the peak areas of analyte versus their corresponding concentration. Values of coefficient of regression, slope and Y-intercept of the calibration curve were calculated.

Accuracy (recovery study)

To perform recovery studies tablet powder was first mixed with Impurity and appropriately diluted to get sample solution. Recovery studies were performed in triplicate at concentration levels i.e., 50, 100 and 150 % by standard addition method. Sample solutions were spiked with appropriate volume of standard solution of Impurity as well as Imatinib mesylate. The resulting mixtures were analysed by the developed method. Base level amount of Imatinib mesylate and its Impurity used for spiking were 20 μ g/ml and 1 μ g/ml, respectively. The % RSD and mean recovery was calculated.

Precision

The precision of the method was verified by repeatability (intraday) and intermediate precision studies. Repeatability was assessed by injecting six times 20 μ l of standard solution containing Imatinib mesylate (20 μ g/ml) spiked with Impurity solution (1 μ g/ml) into HPLC system under stabilized chromatographic conditions and value of % RSD was calculated using peak area of Imatinib mesylate and Impurity. Further inter-day variation for the determination of Imatinib mesylate and Acid Impurity was carried out at three different concentration levels (20, 30 and 40 μ g/ml for Imatinib mesylate and 1, 1.5 and 2 μ g/ml for Acid Impurity) on three

consecutive days. The % RSD of the obtained assay values at three different concentration levels were calculated.

Method sensitivity (limit of detection and limit of quantitation)

The LOD and LOQ were calculated as per ICH guidelines, using equations, $LOD = 3.3 \times \sigma/S$; $LOQ = 10 \times \sigma/S$, respectively where σ is the standard deviation of the y-intercepts and S is the slope of the calibration curve. A series of standard preparation of Imatinib mesylate and Acid Impurity were prepared over different levels. Calibration graphs were plotted for the obtained area under the curve of each level against the concentration. Slope (S) and Standard Deviation were calculated to calculate LOD and LOQ.

Specificity

Specificity involved demonstration of the ability of the developed method for the separation and resolution of Imatinib mesylate and Acid Impurity. Further peak purity of all the analytes was measured to evaluate the specificity of the method. The sample and standard bands were scanned at three distinct levels, i.e., peak start (S), peak apex (M), and peak end (E) positions. The peak purity was determined by PDA detector.

Robustness

Robustness of the method was checked by carrying out the analysis under conditions during which little variations like changing detection wavelength, flow rate and mobile phase composition was done and the effects on the area were noted. The % RSD for each deliberate change was calculated.

Results and Discussion

Development and Optimization

The HPLC procedure was optimized with a target to achieve

separation of Impurity and main component Imatinib mesylate. Based on literature survey and review of physico-chemical properties of analytes, preliminary chromatographic conditions were selected. Chromatographic separation studies were carried out on the resolution solution of Imatinib mesylate (10 $\mu\text{g/ml}$) and Acid Impurity (0.5 $\mu\text{g/ml}$). Initially, trials were carried out using methanol, water in various proportions along with buffer of varying pH, to obtain the desired system suitability parameters. After few trials, mixing methanol and Acetate Buffer pH 3.5 in the ratio of 80: 20 v/v was chosen as the mobile phase which gave good resolution and acceptable peak parameters. Wavelength for monitoring the eluent was selected by scanning standard solution of drug and Impurity within 200–400 nm. Separation was carried out at flow rate of 1 ml/min and detection at 273 nm. The peak purity was checked with the PDA detector. The mobile phase was filtered through a 0.45 μ nylon membrane filter prior to use. The injection volume was 20 μl .

System Suitability

Chromatographic separation of resolution solution D was successfully achieved with the above mentioned chromatographic conditions. Impurity was injected separately as well as by spiking into the Imatinib mesylate to check its interference with the main peak. The Impurities didn't interfere with Imatinib mesylate peak. The resolution between Imatinib mesylate and Acid Impurity was greater than 1.55. The retention times of the Imatinib mesylate and Acid Impurity were 8.083 and 6.208 respectively. The theoretical plates were above 2000 for both Imatinib mesylate and Acid Impurity. Table 1 contains system suitability parameter details of Imatinib mesylate and Acid Impurity.


Table 1: System suitability parameters

S. No.	Imatinib mesylate			Acid Impurity			
	Concentration Injected	Peak Response	Retention Time	Concentration Injected	Peak Response	Retention Time	
1	10	116052.74	8.049	0.5	2420.6	6.226	
2	10	116398.26	8.121	0.5	2410.0	6.189	
3	10	118404.72	8.048	0.5	2402.0	6.212	
4	10	118216.28	8.094	0.5	2452.0	6.199	
5	10	118683.18	8.084	0.5	2582.0	6.216	
6	10	120195.76	8.099	0.5	2501.2	6.205	
Avg.		117991.822	8.083		2461.300	6.208	
SD		1539.849	0.029		69.357	0.013	
RSD		1.305	0.359		2.818	0.211	
Name	RT (Min)	Mean \pm % RSD	Concentration ($\mu\text{g/ml}$)	Avg. Area	Plates (N)	Tailing Factor	Resolution
Acid Impurity		6.208 \pm 0.211	0.5	2461.300	2548.12	1.115	--
Imatinib mesylate		8.083 \pm 0.359	10	117991.822	4056.37	1.028	1.55


Linearity and Range

The method was found to be linear over the range; for Imatinib mesylate it was 10 $\mu\text{g/ml}$ to 60 $\mu\text{g/ml}$ and for Acid Impurity it is 0.5 $\mu\text{g/ml}$ to 3 $\mu\text{g/ml}$. The data generated was

analysed by linear regression analysis shows the satisfactory result with correlation coefficient greater than 0.997. Linearity Curves of Imatinib mesylate and Acid Impurity are shown in Figure 2.



Linearity Curve of Imatinib mesylate



Linearity Curve of Acid Impurity

Fig 2: Linearity Curve of Imatinib mesylate and Acid Impurity.

Accuracy

The % mean recoveries for Imatinib mesylate and Acid Impurity were in the range of 99.95-101.17 and 99.88 – 101.80, respectively. The overall % RSD was observed as less than 2%. Accuracy details are given in Table 2.

Table 2: Accuracy details of Imatinib mesylate and Acid Impurity.

Accuracy Results of Imatinib mesylate				
Accuracy Level	Recovered (mg)	Recovered (%)	Average (%)	SD
50%	10.042	100.4171	101.11	0.84
	10.204	102.0441		
	10.088	100.8821		
100%	20.097	100.4837	99.85	0.55
	19.896	99.4824		
	19.917	99.5825		
150%	29.884	99.6141	99.95	0.88
	29.787	99.2887		
	30.286	100.9528		
Accuracy Results of Acid Impurity				
Accuracy Level	Recovered (mg)	Recovered (%)	Average (%)	SD
50%	0.507550	101.510	99.88	1.55
	0.492154	98.431		
	0.498569	99.714		
100%	1.023948	102.395	101.06	1.46
	1.012722	101.272		
	0.995081	99.508		
150%	1.521101	101.407	101.80	0.45
	1.534252	102.283		
	1.525591	101.706		

Precision and Repeatability

The % RSD in precision studies was found to be 0.22 for repeatability and 0.47– 1.39 % Interday for Imatinib Mesylate. The % RSD in precision studies was found to be 0.82 for repeatability and 0.47– 0.62 % Inter-day for acid impurity. This indicates that the method is precise.

Method sensitivity

The LOD concentration was found to be 0.438, 0.038 µg/ml and LOQ concentration was 1.327, 0.116 µg/ml for Imatinib mesylate and impurity, respectively.

Specificity

The specificity of the method was ascertained by peak purity profiling studies. The peak purity values were found to be more than 993, indicating the no interference of any other peak of degradation product, impurity or matrix. Details about

purity tail and purity front of Imatinib mesylate and Acid Impurity are given in Table 3.

Table 3: Details of Purity tail and Purity front.

Drug/Impurity	Purity tail (s, m)	Purity front (m, e)
Imatinib mesylate	995.32	998.44
Acid Impurity	993.86	995.68

Robustness

Small deliberate alteration in chromatographic conditions did not affect the assay and resolution significantly for the investigated compounds, % RSD was less than 2% indicates that the developed method was robust to minor changes in the experimental conditions. Robustness details are given in Table 4.

Table 4: Robustness details of Imatinib mesylate and Acid Impurity.

Robustness for Imatinib mesylate				
Parameters	Measure	Average	SD	%RSD
Change in Wavelength	273nm	99.517	0.330	0.332
	272nm	100.071	0.118	0.118
	274nm	101.856	0.428	0.421
Change in flow rate	1ml/min	100.031	0.953	0.953
	0.95ml/min	100.380	1.826	1.819
	1.05ml/min	100.245	0.625	0.624
Change in Mobile Phase Composition*	80:20	100.075	0.210	0.210
	82:18	99.799	0.573	0.575
	78:22	100.181	0.528	0.527
Robustness for Acid Impurity				
Parameters	Measure	Average	SD	%RSD
Change in Wavelength	273nm	100.148	1.266	1.264
	272nm	99.706	1.231	1.235
	274nm	99.049	1.132	1.142
Change in flow rate	1ml/min	99.682	1.774	1.780
	0.95ml/min	100.119	0.839	0.838
	1.05ml/min	100.590	1.751	1.741
Change in Mobile Phase Composition*	80:20	100.549	1.224	1.217
	82:18	98.341	1.068	1.086
	78:22	98.978	1.468	1.483

*Methanol: Buffer

Conclusion

The proposed HPLC method for simultaneous estimation of Imatinib mesylate and its Impurity in bulk and Imatinib mesylate tablet was developed and validated as per ICH guidelines. The method was found to be linear in stated range. Statistical analysis proved that the method is specific, accurate, precise and sensitive. The method is suitable for

simultaneous quantitative analysis of Imatinib mesylate and its acid Impurity in bulk drugs and formulations without any interference from the excipients. Thus, the proposed method can be successfully employed for routine quality control and Impurity profiling of Imatinib mesylate.

Acknowledgement

The authors thank Dr. Jagadeesh Kumar Kuna, RMC Kakinada for his encouragement and support in providing necessary support for this work. We greatly acknowledge the receipt of material and research support from Nishka Labs, Hyderabad.

Conflict of interest: Conflict of interest declared none.

References

1. International conference on harmonization, ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology, 2005.
2. International conference on harmonization, ICH Q3A (R2) Impurities in New Drug Substances Q3A (R2), 2006.
3. Yadav RR, Rokade MD, Salunke SA, Gangrade DM, Holkar GS, Daphal VN. Determination of Potential Genotoxic Impurities in Imatinib mesylate by RP-HPLC Method. *Biological Forum – An International Journal* 2012; 4(2):15-18.
4. Venkataramanna Madireddy, Sudhakar Babu Kondra, Narayanareddy P. Stability- Indicative, validated, fast HPLC method for quantification of two genotoxic Impurities in Imatinib mesylate. *Global Journal of Analytical Chemistry*. 2011; 2(5):198-207.
5. Fatma Ghrib, Aymen Chtioui, Taieb Saied, Nizar Bellakhal. Determination of Imatinib and its Genotoxic Impurities in Tablets. *Biological Forum - An International Journal*. 2015; 7(1):1820-1827.
6. Pratik Shah, Rutesh Shah. A stability- indicating RP-HPLC method development and validation for the related substance determination of Imatinib process Impurities and their degradation products in tablet dosage form. *International Journal of Pharm Tech Research*. 2015; 8(6):128-146.